MannKind completes enrollment in Phase 4 trial in diabetes

MannKind has fully enrolled patients in INHALE-3, a Phase 4 clinical trial evaluating inhaled insulin combined with basal insulin versus usual care in adults living with type 1 diabetes. INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. The study will randomly assign participants over 18 years of age with T1D who are using Multiple Daily Injections, an automated insulin delivery system, or a pump without automation to either continue their usual care or adopt an insulin regimen of a daily basal injection plus Afrezza at mealtimes. Both arms will utilize continuous glucose monitoring to assess mealtime control and A1c levels.